Certificate

Brand

Panagene

Product Type

Reagents

Highlights

The PANA RealTyper™ HPV Screening Kit is an in vitro diagnostic reagent for detecting of human papilloma virus (HPV) from common specimen type, cervical swab and liquid based cytology (LBC) sample.

The PANA RealTyper™ HPV Screening Kit is a CE marked diagnostic device in accordance with the European Union in vitro Diagnostic Medical Device Directive 98/79/EC

Application

The PANA RealTyper™ HPV Screening Kit is an in vitro diagnostic reagent for detecting of human papilloma virus (HPV) from common specimen type, cervical swab and liquid based cytology (LBC) sample. This kit is an amplified DNA test for the qualitative detection of a total of 14 high-risk (HR) HPV types and 2 low-risk (LR) HPV types in a real-time PCR (polymerase chain reaction) system. This kit specially identifies 2 HR types such as 16 and 18 and 2 LR types such as 6 and 11 while concurrently detecting the other HR HPV types that includes 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.

Other information

▶ Supplier

Panagene

▶ Order Information:

PANARealTyperTM HPV Screening Kit

Code: PNAM-5001

Package: 96 Tests/Kit

Related Products

EntroGen’s BRCA Complete™ Expanded Panel

EntroGen’s BRCA Complete™ Expanded Panel is a comprehensive NGS solution that detects both germline and somatic mutations in genes like BRCA1, BRCA2, CHEK2, PALB2, RAD51C, and TP53 with high sensitivity and specificity. Compatible with blood, fresh frozen, and FFPE samples, the panel reduces allele dropouts and off-target reads using a tiled amplicon PCR approach. It includes reagents for library preparation and user-friendly software for easy mutation identification, along with quality control assays to ensure high-quality data without repeat sequencing.

Illumina COVIDSeq ™ Assay (96 samples)

Certificate: ROU 

Supplier: Illumina 

For Mid and Low-throughput laboratories performing COVID-19 surveillance and identification of new variants

BRCAaccuTest™ & BRCAaccuTest™PLUS

BRCAaccuTest™ PLUS with CE-IVD certificate for HBOC Breast/Ovarian Cancer Test

BRCAaccuTest™ & BRCAaccuTest™PLUS

BRCAaccuTest™ & BRCAaccuTest™PLUS is a regent for producing libraries for
analyzing the BRCA ½ genes using the NGS (next-generation sequencing) method,
which analyzes genomic DNA derived from blood or FFPE tissues.

Next-Generation Sequencing System – NextSeq 2000

 The NextSeq 2000 Sequencing System uses patterned flow cells similar to those that power the NovaSeq™ 6000 System. The result is a highly flexible and scalable benchtop system that offers the highest cluster density flow cell of any on-market NGS system to date, driving down the cost per gigabase (Gb) of the sequencing run.

NextSeq 1000 sequencing system

Product Information

Model: NextSeq 1000

Manufacturer: Illumina

Origin: Singapore/United States

Launching year: 01/2020

PANARealTyperTM HPV Kit

PANA RealTyperTM HPV Kit is a CE marked diagnostic device in accordance with the European Union in vitro Diagnostic Medical Device Directive 98/79/EC.

Next-Generation Sequencing System – NovaSeq 6000

Model: NovaSeq 6000
Manufacturer: Illumina/USA
– Scalable platform
Match data output, time to results, and price per sample to study needs
– Flexible performance
Configure sequencing method, flow cell type, and read length to support a broad range of applications
– Streamlined operation
Increase lab efficiency with a simplified workflow and reduced hands-on time

Next Generation Sequencing System – iSeq 100

Model: iSeq 100
Manufacturer: Illumina/USA
Illumina’s smallest next-generation DNA sequencing system, with small, fast and efficient sequencing throughput, suitable for all labs
– Fast data generation: Suitable for small projects, on a dedicated device, low throughput with fast turnaround times
– Convenient operation: Control the sequencing process from start to finish and ensure independent sequencing instead of outsourcing.

TruSight Cancer Sequencing Panel

Developed with cancer genomics experts in collaboration, oligos ready-to-use, pre-engineered oligos allow researchers to sequence a wide range of genes and single nucleotide polymorphisms (SNPs) in advance. this is related to cancer predisposition